摘要
目的探究雷公藤红素(celastrol)诱导细胞内活性氧(reactive oxygen species,ROS)产生在介导细胞DNA损伤中的作用及对肝癌细胞凋亡的影响。方法人肝癌细胞经雷公藤红素处理后,镜下观察细胞形态变化;MTT法测定肝癌细胞的存活率;Hoechst 33258染色观察肝癌细胞核变化;流式细胞术检测细胞死亡;CM-H2DCFDA探针检测细胞内ROS水平;免疫荧光方法检测细胞内DNA损伤标志蛋白γ-H2AX的荧光强度;Western blot检测γ-H2AX、caspase-3、PARP等蛋白表达水平。结果雷公藤红素可显著抑制肝癌细胞的存活,并可升高细胞内ROS水平,呈浓度依赖性关结论雷公藤红素可诱导肝癌细胞内ROS聚集,高水平的ROS引起细胞DNA损伤,最终诱导细胞凋亡。
Aim To investigate the role of celastrol in reactive oxygen species(ROS)accumulation and DNA damage in hepatocellular carcinoma cells,and further investigate its effect on apoptosis induction in cancer cells.Methods Human liver cancer HepG2 and Huh7 cells were cultured with celastrol,then the morphological changes of cells were observed under microscope.MTT assay was employed to detect the proliferation of hepatocellular carcinoma cells,CM-H2DCFDA probe to detect intracellular ROS levels,and immunofluorescence to detect the expression level ofγ-H2AX in celastrol-treated cells.Hoechst 33258 staining was used to observe nuclear condensation and fragmentation;Flow cytometry was used to evaluate cell death.Western blot was applied to measure the expression levels ofγ-H2AX,caspase-3,PARP and other proteins.Results Celastrol had a significant inhibitory effect on the proliferation of liver cancer cells in dose-dependent manner.Compared with the control group,the cell viability was reduced and intracellular ROS level also increased significantly after celastrol treatment in a dose-dependent manner(P<0.05).With Hoechst staining,typical apoptotic characteristics such as nuclear chromatin condensation and fragmentation were observed in celastrol-treated cells.Western blot results showed that pro-form of caspase-3 significantly decreased,and the cleavage of PARP markedly increased by celastrol.After pretreatment with ROS inhibitor NAC,celastrol-mediated caspase-3 activation and PARP cleavage were significantly reversed(P<0.05).Conclusions Celastrol can induce apoptosis in hepatocellular carcinoma cells,and its anti-cancer effect is dependent on ROS-mediated DNA damage.
作者
马静
王红磊
王梓萱
李昕宇
李美秀
吴勇
刘禹佳
卢国栋
周静
MA Jing;WANG Hong-lei;WANG Zi-xuan;LI Xin-yu;LI Mei-xiu;WU Yong;LIU Yu-jia;LU Guo-dong;ZHOU Jing(Dept of Physiology, School of Preclinical Medicine,Guangxi Medical University, Nanning 530021, China;Dept of Physiology, School of Preclinical Medicine, Guangxi University of Chinese Medicine, Nanning 530200, China;Dept of Toxicology, School of Public Health, Guangxi Medical University, Nanning 530021, China)
出处
《中国药理学通报》
CAS
CSCD
北大核心
2022年第3期366-372,共7页
Chinese Pharmacological Bulletin
基金
国家自然科学基金资助项目(No 81972291)
广西自然科学基金重点项目(No 2017GXNSFDA198020)
广西中医药大学2019-2021年广西一流学科建设开放课题(No 2019XK087)
广西壮瑶药重点实验室建设项目(No GXZYKF2020-05)。